(Q24247141)

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Lactulose in the treatment of chronic portal-systemic encephalopathy. A double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Lactitol versus lactulose in the treatment of chronic hepatic encephalopathy. A double-blind, randomised, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomised, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Lactitol, a second-generation disaccharide for treatment of chronic portal-systemic encephalopathy. A double-blind, crossover, randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Treatment of chronic portal-systemic encephalopathy with lactulose. Report of six patients and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Lactulose Treatment of Hepatic Encephalopathy in Outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Lactitol in the treatment of chronic hepatic encephalopathy: an open comparison with lactulose

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Comparative modes of action of lactitol and lactulose in the treatment of hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Branched-chain amino acids vs lactulose in the treatment of hepatic coma: a controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Effects of long-term administration of low-dose lactitol in patients with cirrhosis but without overt encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

PORTAL-SYSTEMIC ENCEPHALOPATHY NEUROLOGICAL COMPLICATIONS OF LIVER DISEASE

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Treatment of chronic portal-systemic encephalopathy with lactose in lactase-deficient patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Interaction revisited: the difference between two estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

A clinical hepatologist's predictions about non-absorbed carbohydrates for the early twenty-first century

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Methods for combining randomized clinical trials: strengths and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

The performance of the two-stage analysis of two-treatment, two-period crossover trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Screening of subclinical hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

What is meant by intention to treat analysis? Survey of published randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Management of hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

A Multiple Testing Procedure for Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Use of the equivalence approach in reproductive health clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Recent developments in the pathophysiology and treatment of hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

Blindness induced by double-blindedness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

7 January 2021

Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

7 January 2021

Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

7 January 2021

Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

7 January 2021

Oral zinc supplementation improves hepatic encephalopathy. Results of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

7 January 2021

Lactitol versus lactulose in the treatment of acute portal systemic encephalopathy (PSE)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

7 January 2021

Lactitol vs. lactulose in the treatment of chronic recurrent portal-systemic encephalopathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

7 January 2021

Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

7 January 2021

Comparison of the absorption and metabolic products of sucrose and its monosaccharides in man

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

7 January 2021

Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

7 January 2021

Minimal hepatic encephalopathy: a permanent source of discussion

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

7 January 2021

Effect of Lactitol and Lactulose Administration on the Fecal Flora in Cirrhotic Patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

7 January 2021

The Effect of Lactulose and Lactitol Administration on Fecal Fat Excretion in Patients with Liver Cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

7 January 2021

Long-term treatment of portal-systemic encephalopathy with lactulose

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003044.PUB2

7 January 2021

10.1002/14651858.CD003044.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

15106187

1 reference

Consolidated OpenCitations Corpus – April 2017